Aethlon Medical, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended December 31, 2014; filed February 10, 2015. The company develops therapeutic blood-filtration devices and exosome-based diagnostics. Reported revenue came from government contracts, not commercial product sales.
Financial performance and liquidity
- Revenue: Quarter revenue was $33,434, down from $76,313 a year earlier. Nine-month revenue was $563,805, down 38% from $916,796. Nine-month revenue included $444,723 from DARPA milestones and $119,082 from a Battelle subcontract; Exosome Sciences had no revenue.
- Losses and expenses: Quarterly operating loss was $1.087 million versus $1.232 million; net loss attributable to common stockholders was $1.550 million versus $2.231 million. For nine months, operating loss widened to $2.860 million from $2.246 million, and net loss attributable to common stockholders was $5.910 million versus $5.884 million. Nine-month loss per share was $0.02 versus $0.03.
- Cash flow: Nine-month operating cash use increased to $3.152 million from $1.584 million. Financing provided $4.677 million, including $4.763 million of net common-stock proceeds and $415,000 from notes; cash increased by $1.525 million.
- Balance sheet at December 31: Cash was $2.776 million, current assets $2.969 million, current liabilities $1.598 million, and working capital $1.372 million. Total liabilities were $1.862 million. The company had an accumulated deficit of $80.743 million and total equity of $1.295 million. Related-party amounts due were $810,381.
- Debt and dilution: Convertible notes had $729,939 principal outstanding, presented at a net carrying amount of $264,252 after discounts. The November 2014 notes carried 10% interest, matured April 2016, and were convertible at $0.112 per share. Shares outstanding increased from 224.97 million at March 31 to 327.74 million at December 31; 330.30 million were outstanding February 10, 2015. Warrants outstanding totaled 71.79 million.
- Margins: The filing does not present a gross-margin figure; revenue remained small relative to operating costs and the company reported operating losses.
Material changes and unusual items
- Nine-month operating expenses rose 8.3% to $3.424 million, reflecting higher payroll and general and administrative costs, partly offset by lower professional fees. Clinical-trial expenses of $192,243 were recorded in the 2014 period.
- Nine-month other expense included a $2.754 million loss on debt conversions. Derivative liabilities of $10.679 million were reclassified to equity after holders waived anti-dilution protections; this materially improved reported working capital but did not represent operating cash generation.
- The company raised $3.3 million in a December equity-and-warrant financing, with reported net proceeds of approximately $3.0 million. It also issued substantial shares and warrants through conversions and warrant exercises, including cashless exercises that generated no proceeds.
- At March 31, 2014, working capital was negative $14.169 million; the subsequent improvement primarily reflected the derivative-liability reclassification, debt changes, and financing, rather than profitable operations.
Outlook, risks, and contingencies
- Management stated that cash at December 31 plus financing raised by the filing date was not sufficient for the next 12 months. Additional financing is required to fund operations and complete the U.S. clinical trial; management expects continued losses and negative cash flows. The filing identifies substantial doubt about the company’s ability to continue as a going concern.
- The FDA had authorized a ten-patient Hemopurifier feasibility study for dialysis patients with hepatitis C; the first patient enrolled in February 2015. Successful completion and follow-on trials are needed before U.S. commercialization. The filing gives no assurance of regulatory approval, financing, or commercial acceptance.
- DARPA’s contract scope was reduced in February 2014, lowering possible payments by $858,491 over years three through five. Year five remained an option, and milestone achievement and payment were not assured. Management also warned that non-exercise of that option could materially affect revenue and liquidity.
- The company reported ineffective disclosure controls and procedures as of period-end. It reported no pending or threatened legal proceedings; leases and ordinary-course claims remain disclosed contingencies.
- Subsequent events included $68,063 paid to retire remaining 12% notes and a $100,000 note conversion into 2.38 million shares. The filing’s liquidity discussion and Note 2 contain differing assessments of whether expected funds could cover fiscal 2015 needs; the MD&A explicitly says funding for the next 12 months was insufficient.
Important facts for investors to verify
- Current cash, cash runway, and completion and terms of any financing after February 10, 2015.
- Clinical-trial enrollment, progress, costs, and required follow-on studies, alongside FDA and foreign regulatory milestones.
- DARPA year-five option status, remaining milestone requirements, and the effect of the contract scope reduction on future receipts.
- Fully diluted share count, including outstanding warrants, options, and convertible notes, and potential dilution from conversions or exercises.
- Remediation plans and progress regarding ineffective disclosure controls, and the company’s ability to address the going-concern uncertainty.